VK
Vinu Krishnan
AbbVie, Intellia Therapeutics (United States), Harvard University Wyss Institute for Biologically Inspired Engineering, University of California Santa Barbara, Fount Bio, Inc., University of Delaware
0000-0003-0098-7864
Employment
-
AbbVie Principle Research Scientist2025 - Present
-
Intellia Therapeutics (United States) Senior Scientist / Principle Scientist2021 - 2025
-
Fount Bio, Inc. Scientist II2019 - 2021
Education
-
Harvard University Wyss Institute for Biologically Inspired Engineering Research Fellow2018 - Present
-
University of California Santa Barbara Research Scholar2015 - 2017
-
University of Delaware PhD2009 - 2015
-
University of Akron Master of Science in Engineering2005 - 2008
Projects & Funding
Projects & funding information is unavailable.
Publications (20)
- Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma Save
- Hyaluronic acid conjugates for topical treatment of skin cancer lesions Save
- Hyaluronic acid–doxorubicin nanoparticles for targeted treatment of colorectal cancer Save
- Injectable hyaluronic acid hydrogels encapsulating drug nanocrystals for long-term treatment of inflammatory arthritis Save
- Optimized 5-fluorouridine prodrug for Co-loading with doxorubicin in clinically relevant liposomes Save
- Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases Save
- Design principles of drug combinations for chemotherapy Save
- Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function Save
- Hyaluronic Acid Conjugates of Vorinostat and Bexarotene for Treatment of Cutaneous Malignancies Save
- Nanoparticles for topical drug delivery: Potential for skin cancer treatment Save